2 Patients Randomized. $3,000 Per Randomized Patient.

Some enrollment challenges are not about volume. They are about precision. This AstraZeneca-sponsored COPD study site needed to fill two randomization slots within a fixed protocol window. A missed slot could not be recovered. The timeline was defined.

Traditional recruitment vendors carried the same structural risk that affects most sites working with externally sourced patient recruitment: fees payable regardless of whether patients are randomized. For a small, targeted enrollment need with no room for error, that financial structure was not acceptable. The site needed a partner accountable for outcomes, not activity.

At $6,000 in campaign investment, the question was whether a recruitment partner could commit, contractually, to delivering within it.

The campaign delivered 2 randomized patients against a $6,000 investment, a cost per randomized patient of $3,000.

Per-patient site fees in Phase II-III trials typically range from $3,000 to $15,000 per randomized patient. At an estimated $3,000 to $15,000 per-patient site fee, two randomized patients represents a potential $6,000 to $30,000 in patient revenue against a $6,000 campaign investment.

For this site, the more material outcome was protocol adherence: the enrollment window was met, the sponsor relationship was maintained, and the site incurred no financial exposure when the campaign was initiated. The contractual commitment transferred recruitment risk to Clinical Enroll before a dollar was spent.